McDowell, P. J., Diver, S., Yang, F., Borg, C., Busby, J., Brown, V., Shrimanker, R., Cox, C., Brightling, C. E., Chaudhuri, R., Pavord, I. D., Heaney, L. G., , , McDowell, P. J., Diver, S., Yang, F., Borg, C., Busby, J., Brown, V., Shrimanker, R., Cox, C., Brightling, C. E., Chaudhuri, R., Pavord, I. D., Heaney, L. G., Wise, C., McAnally, C., Drain, S., Mistry, V., Arnold, H., Micieli, C., Monterio, , Jones, M., Ellis, H., Thulborn, S., Cheyne, L., Ramsey, E., Howes, S., Bourne, M., Thorton, T., Edwards, S., Evans, H., Smith, S., & Grandison, T. (2021). the inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study. Lancet, 9(10), 1174–1184. http://access.bl.uk/ark:/81055/vdc_100144486583.0x000011